McCullough PA, et al. - Researchers used the Premier Hospital Database and evaluated the rate of major adverse renal or cardiac events (MARCE) associated with the use of iohexol vs other low osmolar contrast media (LOCMs) during interventional cardiovascular procedures. They analyzed data for 458,091 patient encounters with an inpatient primary interventional cardiovascular procedure with a single LOCM (iohexol, ioversol, ioxilan, ioxaglate, or iopamidol), of these 26% used iohexol and 74% used other LOCMs. They assessed the aforementioned link by using multivariable regression analysis, while controlling for patient demographics, comorbid conditions and reason for hospitalization. As a sensitivity analysis, direct comparisons of iohexol were made to other LOCMs. Findings revealed no differences in MARCE events with iohexol vs other LOCMs during inpatient interventional cardiovascular procedures in this retrospective multicenter study.